SymbioCellTech, LLC 1/12/21 SymbioCellTech, LLC 1/12/21 Virbac and Symbiocelltech sign exclusive option agreement to develop novel technology for treatment of type 1 diabetes in companion animals. Read More SymbioCellTech, LLC 9/19/19 SymbioCellTech, LLC 9/19/19 Interim report on the effective intraperitoneal therapy of insulin-dependent diabetes mellitus in pet dogs using “Neo-Islets,” aggregates of adipose stem and pancreatic islet cells (INAD 012-776) Read More SymbioCellTech, LLC 9/6/19 SymbioCellTech, LLC 9/6/19 SymbioCellTech Completes Pre-IND Meeting with FDA: Critical Step Toward Human Trials Read More SymbioCellTech, LLC 7/10/19 SymbioCellTech, LLC 7/10/19 FDA Grants SymbioCellTech Pre-IND Meeting for Novel Neo-Islet Stem Cell Therapy for Diabetes Read More SymbioCellTech, LLC 6/20/19 SymbioCellTech, LLC 6/20/19 Pre-IND Package Submitted to Center for Biologics Evaluation and Research (CBER) by SymbioCellTech Read More SymbioCellTech, LLC 6/11/19 SymbioCellTech, LLC 6/11/19 SymbioCellTech Scientific Team Presents Neo-Islet Data at ADA 2019 Read More SymbioCellTech, LLC 6/6/19 SymbioCellTech, LLC 6/6/19 SymbioCellTech Earns Certificate of Achievement for Being Amongst Most Downloaded Papers of 2017 & 2018 Read More SymbioCellTech, LLC 4/24/19 SymbioCellTech, LLC 4/24/19 SymbioCellTech Greenlighted to Submit FDA Pre-IND to CBER Read More SymbioCellTech, LLC 4/11/19 SymbioCellTech, LLC 4/11/19 SymbioCellTech submits INTERACT Package to FDA Center for Biologics Evaluation and Research (CBER) Read More SymbioCellTech, LLC 6/29/18 SymbioCellTech, LLC 6/29/18 SymbioCellTech Presents Preliminary Data from First-of-Its-Kind Dog Study at American Diabetes Association Meeting Read More Newer Posts Older Posts
SymbioCellTech, LLC 1/12/21 SymbioCellTech, LLC 1/12/21 Virbac and Symbiocelltech sign exclusive option agreement to develop novel technology for treatment of type 1 diabetes in companion animals. Read More
SymbioCellTech, LLC 9/19/19 SymbioCellTech, LLC 9/19/19 Interim report on the effective intraperitoneal therapy of insulin-dependent diabetes mellitus in pet dogs using “Neo-Islets,” aggregates of adipose stem and pancreatic islet cells (INAD 012-776) Read More
SymbioCellTech, LLC 9/6/19 SymbioCellTech, LLC 9/6/19 SymbioCellTech Completes Pre-IND Meeting with FDA: Critical Step Toward Human Trials Read More
SymbioCellTech, LLC 7/10/19 SymbioCellTech, LLC 7/10/19 FDA Grants SymbioCellTech Pre-IND Meeting for Novel Neo-Islet Stem Cell Therapy for Diabetes Read More
SymbioCellTech, LLC 6/20/19 SymbioCellTech, LLC 6/20/19 Pre-IND Package Submitted to Center for Biologics Evaluation and Research (CBER) by SymbioCellTech Read More
SymbioCellTech, LLC 6/11/19 SymbioCellTech, LLC 6/11/19 SymbioCellTech Scientific Team Presents Neo-Islet Data at ADA 2019 Read More
SymbioCellTech, LLC 6/6/19 SymbioCellTech, LLC 6/6/19 SymbioCellTech Earns Certificate of Achievement for Being Amongst Most Downloaded Papers of 2017 & 2018 Read More
SymbioCellTech, LLC 4/24/19 SymbioCellTech, LLC 4/24/19 SymbioCellTech Greenlighted to Submit FDA Pre-IND to CBER Read More
SymbioCellTech, LLC 4/11/19 SymbioCellTech, LLC 4/11/19 SymbioCellTech submits INTERACT Package to FDA Center for Biologics Evaluation and Research (CBER) Read More
SymbioCellTech, LLC 6/29/18 SymbioCellTech, LLC 6/29/18 SymbioCellTech Presents Preliminary Data from First-of-Its-Kind Dog Study at American Diabetes Association Meeting Read More
